Figure 1.

Neuroimaging testing in the diagnostic tracking of LGI1 AE. Neuroimaging testing plays an essential role in the diagnosis of LGI1 AE. The sensitivity of ¹⁸F-FDG-PET was higher than that of MRI; the ¹⁸F-FDG-PET scan was always positive when the MRI was positive, but when the MRI scan was negative for the diagnosis of LGI1 AE, 79% of the patients were still positive on the ¹⁸F-FDG-PET scan. LGI1, leucine-rich glioma-inactivated 1; AE, autoimmune encephalitis; EEG, electroencephalogram; MRI, magnetic resonance imaging; PET, ¹⁸F-fluoro-2-deoxy-d-glucose positron emission tomography; +, positive; –, negative.